You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 8 Next »

  1. SEND Home on the CDISC Website
  2. SEND Home on the CDISC Wiki (Access may be restricted to SEND Team Members)

SEND Leadership Team (SLT)

  • TBD (Incoming Leader) (a)
  • William Houser (Leader) (a)
  • Lou Ann Kramer (Past Leader) (a)
  • Chris Gemma (CDISC Liaison) (a)

SEND Leadership Team Extended (SLTX)

  • William Houser (Leader) (a)
  • Lou Ann Kramer (Past Leader) (a)
  • Chris Gemma (CDISC Liaison) (a)
  • Brian Argo
  • Kathryn Brown
  • Mary Jo Brucker
  • Sue DeHaven (PhUSE Liaison)
  • Marc Ellison
  • Gitte Frausing
  • Jamie Gilliam
  • Mattew Hayes
  • Christy Kubin
  • Louis Norton (b)
  • Debra Oetzman
  • Dan Potenta
  • Ben Sefing
  • Troy Smyrnios (b)
  • Erin Tibbs-Slone
  • Audrey Walker (b)
  • Michael Wasko
  • Fred Wood (b and Past Leader)
  • Craig Zwickl
  • FDA CBER Liaisons:
    • Virginia Hussong
    • Lisa Lin
    • Elaine Thompson
  • FDA CDER Liaisons
    • Crystal Allard
    • Dave Epstein
    • Kevin Snyder
    • Helena Sviglin
    • Kendra Worthy

a- CDISC TLC (Technical Leadership Committee) member

b- CDISC Cross-team Governance member

SEND Change Control Board (CCB)

  • Jamie Gilliam (Leader)
  • William Houser
  • Lou Ann Kramer
  • Louis Norton
  • Debra Oetzman
  • Audrey Walker
  • Fred Wood
  • FDA Liaison: Patricia Brundage

SEND Sub-teams (leader)

SEND Controlled Terminology: Craig Zwickl 

Reproductive Toxicology (and Pilot): Mary Jo Brucker

SEND Conformation Rules: Christy Kubin

SEND IG/CCB: Jamie Gilliam

FDA CDER Pilot Liaisons: Elaine Thompson, Helena Sviglin, and David Epstein

PhUSE Liaison: Susan DeHaven

Team Mission and Scope

The CDISC SEND team develops standards that support both the regulatory submission of nonclinical data as well as the operational use and exchange of nonclinical data throughout the industry.

This team is responsible for overall development and maintenance of the production SEND IG (Implementation Guide) versions and their alignment with the SDTM. 

Production releases of the SEND standard:

Standard & VersionSupplemental Materials

SENDIG v3.0, rel. 17June2011 (supports single- and repeat- dose general toxicology and carcinogenicity study data)

Confirmed Data Endpoints for SENDIG v3.0 Data Exchange
(CoDEx 1.0 for SEND v3.0), rel. 16Aug2017

SENDIG v3.1, rel. 07July2016 (supports single- and repeat- dose general toxicology and carcinogenicity study data)
The above deliverables are available to the public at: www.cdisc.org/SEND. 

SEND Team Structure and Operations

Core Team membership is open to all interested parties with over eighty-five members currently.
Sub-teams formed to manage long-term subject areas.
Change Control Board (CCB) assesses and recommends action on changes requested regarding the production SEND IG.
SEND Leadership Team (SLT) sets direction for the team, with representation from the CDISC TLC.
• Work-Streams initiated by the SLT and CCB for all tasks that are not within the scope of the aforementioned sub-teams and expected to have a clear start and end (ie, shorter term need).

SEND Work-Stream Leaders and Cross-team Integrators

When a task, issue or group of issues is identified for a Work-Stream, by the SEND CCB, an experienced SEND member leads or mentors a newer leader for the Work-Stream and reports back to the CCB and Core Team until the topics reach closure.

Jennifer Feldmann, Gitte Frausing, Brandy Harter, William Houser, Lou Ann Kramer, Louis Norton, Debra Oetzman, Troy Smyrnios, Audrey Walker, Fred Wood, Peggy Zorn

Collaborations and Meetings

The SEND Team maintains representatives on the CDISC cross-team governance in addition to a long-standing practice of working closely with the CDISC SDS, Controlled Terminology, and XML Technologies teams. With the release of SENDIG-DART v1.1,the SEND is working closely with the CDISC SHARE effort.

The SEND team partners with the INHAND organization for pathology-related terminology (http://www.toxpath.org/inhand.asp). SEND also has a strong presence on the FDA/PhUSE Computational Sciences Symposium (CSS) (http://www.phuse.eu/css), including several leadership positions and significant overlap in membership with the Nonclinical Topics working group.


• SEND Core Team meets monthly on Wednesdays for 90 minutes. Active members meet face-to-face at the FDA two times each year.
• SEND sub-teams and CCB meet bi-weekly. Work-streams meet as needed.
• FDA/PhUSE CSS Working Group sub-teams meet regularly via teleconference.


Stakeholders/Constituency

• Regulatory Authorities
• Pharmaceutical Sponsors
• Nonclinical Research Scientists & Pathologists
• Contract Research Organizations
Independent Consultants
• Information Technology Tool Developers
Service Providers


SEND datasets are accepted now and will be required in future FDA Submissions per the following guidances:
•“Providing Regulatory Submissions in Electronic Format – Submissions Under Section 745A(a) of the Federal Food, Drug, and Cosmetic Act” - parent guidance
•“Providing Regulatory Submissions in Electronic Format – Standardized Study Data”
•“Study Data Technical Conformance Guide”

  • No labels